肿瘤学中的无创连续体温监测及未来方向
Noninvasive Continuous Temperature Monitoring in Oncology and Future Directions.
作者信息
Bradley Sarah K, Phillips Ruth Anne, Jani Janvi
机构信息
Sarah K. Bradley.
Ruth Anne Phillips.
出版信息
Clin J Oncol Nurs. 2025 May 19;29(3):E70-E78. doi: 10.1188/25.CJON.E70-E78.
BACKGROUND
This review describes the current state of noninvasive continuous temperature monitoring (CTM) in oncology and future directions for CTM.
OBJECTIVES
MEDLINE®, Google Scholar™, and ClinicalTrials.gov databases were searched for articles published from April 1, 2019, to April 30, 2024, to evaluate the use of wearable CTM devices. The validity of the evidence and the regulatory status of U.S. Food and Drug Administration 510(k)-cleared devices were assessed to determine the benefits and limitations of using CTM for detecting febrile neutropenia.
METHODS
In total, 178 unique studies were screened, 64 were selected for additional review, and 15 met inclusion criteria and used one of four brands of 510(k)-cleared medical-grade devices.
FINDINGS
The benefits of CTM identified in this review include improved patient outcomes, increased cost savings, ease and reliability of use, increased patient mobility, and the ability to wirelessly and remotely monitor patients. The feasibility, usability, and satisfaction in patients and caretakers were established.
背景
本综述描述了肿瘤学中非侵入性连续体温监测（CTM）的现状以及CTM的未来发展方向。
目的
检索MEDLINE®、Google Scholar™和ClinicalTrials.gov数据库中2019年4月1日至2024年4月30日发表的文章，以评估可穿戴CTM设备的使用情况。评估证据的有效性以及美国食品药品监督管理局510(k)批准设备的监管状态，以确定使用CTM检测发热性中性粒细胞减少症的益处和局限性。
方法
共筛选了178项独特的研究，选择64项进行进一步审查，15项符合纳入标准并使用了四个品牌之一的510(k)批准的医疗级设备。
结果
本综述确定的CTM的益处包括改善患者预后、增加成本节约、使用方便和可靠、增加患者活动能力以及无线和远程监测患者的能力。确定了患者和护理人员的可行性、可用性和满意度。
Zotero 插件